LONDON-- GlaxoSmithKline PLC (GSK.LN) said a review of data from a phase III trial of losmapimod for heart treatment “did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study as currently designed.”
GSK’s also said its Advair Diskus achieved its primary endpoint in a safety study of patients with asthma and that its shingles treatment Shingrix demonstrated “90% efficacy against shingles in people 70 years of age and over” in a Phase III trial.
Help employers find you! Check out all the jobs and post your resume.
